Liquid Biopsy: Paving a New Avenue for Cancer Research

Overview

Journal Cell Adh Migr

Specialty Cell Biology

Date 2024 Sep 2

PMID 39219215

Authors

Keerthi Kurma

Zahra Eslami-S

Catherine Alix-Panabieres

Laure Cayrefourcq

Affiliations

Soon will be listed here.

Abstract

The current constraints associated with cancer diagnosis and molecular profiling, which rely on invasive tissue biopsies or clinical imaging, have spurred the emergence of the liquid biopsy field. Liquid biopsy involves the extraction of circulating tumor cells (CTCs), circulating free or circulating tumor DNA (cfDNA or ctDNA), circulating cell-free RNA (cfRNA), extracellular vesicles (EVs), and tumor-educated platelets (TEPs) from bodily fluid samples. Subsequently, these components undergo molecular characterization to identify biomarkers that are critical for early cancer detection, prognosis, therapeutic assessment, and post-treatment monitoring. These innovative biosources exhibit characteristics analogous to those of the primary tumor from which they originate or interact. This review comprehensively explores the diverse technologies and methodologies employed for processing these biosources, along with their principal clinical applications.

References

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

Best M, Sol N, In t Veld S, Vancura A, Muller M, Niemeijer A . Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell. 2017; 32(2):238-252.e9. PMC: 6381325. DOI: 10.1016/j.ccell.2017.07.004. View

Friedlander T, Ngo V, Dong H, Premasekharan G, Weinberg V, Doty S . Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer. 2013; 134(10):2284-93. DOI: 10.1002/ijc.28561. View

Kato S, Weipert C, Gumas S, Okamura R, Lee S, Sicklick J . Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. JCO Precis Oncol. 2021; 5. PMC: 8585281. DOI: 10.1200/PO.21.00011. View

Meddeb R, Pisareva E, Thierry A . Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. Clin Chem. 2019; 65(5):623-633. DOI: 10.1373/clinchem.2018.298323. View

Halvorsen A, Sandhu V, Sprauten M, Flote V, Kure E, Brustugun O . Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta Oncol. 2018; 57(9):1225-1231. DOI: 10.1080/0284186X.2018.1465585. View

Kim Y, Koo K, Sung J, Yun U, Kim H . Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol. 2012; 2012:306879. PMC: 3296207. DOI: 10.1155/2012/306879. View

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

10.

Perakis S, Speicher M . Emerging concepts in liquid biopsies. BMC Med. 2017; 15(1):75. PMC: 5382440. DOI: 10.1186/s12916-017-0840-6. View

11.

Kato S, Krishnamurthy N, Banks K, De P, Williams K, Williams C . Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res. 2017; 77(16):4238-4246. PMC: 5729906. DOI: 10.1158/0008-5472.CAN-17-0628. View

12.

Rzhevskiy A, Kapitannikova A, Malinina P, Volovetsky A, Aboulkheyr Es H, Kulasinghe A . Emerging role of circulating tumor cells in immunotherapy. Theranostics. 2021; 11(16):8057-8075. PMC: 8315079. DOI: 10.7150/thno.59677. View

13.

Eslami-S Z, Cortes-Hernandez L, Glogovitis I, Antunes-Ferreira M, DAmbrosi S, Kurma K . cross-talk between metastasis-competent circulating tumor cells and platelets in colon cancer: a malicious association during the harsh journey in the blood. Front Cell Dev Biol. 2023; 11:1209846. PMC: 10433913. DOI: 10.3389/fcell.2023.1209846. View

14.

Pantel K, Speicher M . The biology of circulating tumor cells. Oncogene. 2015; 35(10):1216-24. DOI: 10.1038/onc.2015.192. View

15.

Lichtman M, Chamberlain J, Simon W, Santillo P . Parasinusoidal location of megakaryocytes in marrow: a determinant of platelet release. Am J Hematol. 1978; 4(4):303-12. DOI: 10.1002/ajh.2830040402. View

16.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

17.

Drula R, Ott L, Berindan-Neagoe I, Pantel K, Calin G . MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods. Cancers (Basel). 2020; 12(8). PMC: 7465219. DOI: 10.3390/cancers12082009. View

18.

Overman M, Modak J, Kopetz S, Murthy R, Yao J, Hicks M . Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. J Clin Oncol. 2012; 31(1):17-22. PMC: 5545102. DOI: 10.1200/JCO.2012.43.1718. View

19.

Nikolaev S, Lemmens L, Koessler T, Blouin J, Nouspikel T . Circulating tumoral DNA: Preanalytical validation and quality control in a diagnostic laboratory. Anal Biochem. 2017; 542:34-39. DOI: 10.1016/j.ab.2017.11.004. View

20.

Kuhlmann J, Wimberger P, Bankfalvi A, Keller T, Scholer S, Aktas B . ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem. 2014; 60(10):1282-9. DOI: 10.1373/clinchem.2014.224808. View